ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 77 filers reported holding ALPINE IMMUNE SCIENCES INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,933,490 | +17.7% | 605,545 | +5.7% | 0.00% | – |
| Q2 2023 | $5,888,816 | +120.0% | 572,842 | +65.2% | 0.00% | – |
| Q1 2023 | $2,676,300 | -40.0% | 346,671 | -42.9% | 0.00% | – |
| Q4 2022 | $4,460,244 | +122.0% | 606,836 | +117.5% | 0.00% | – |
| Q3 2022 | $2,009,000 | -11.9% | 278,982 | +4.1% | 0.00% | – |
| Q2 2022 | $2,281,000 | +15.3% | 268,082 | +21.5% | 0.00% | – |
| Q1 2022 | $1,979,000 | -30.6% | 220,621 | +7.1% | 0.00% | – |
| Q4 2021 | $2,853,000 | +35.2% | 206,012 | +4.2% | 0.00% | – |
| Q3 2021 | $2,110,000 | +35.4% | 197,796 | +14.3% | 0.00% | – |
| Q2 2021 | $1,558,000 | +2334.4% | 173,119 | +1609.6% | 0.00% | – |
| Q3 2018 | $64,000 | – | 10,126 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 4,708,288 | $42,233,000 | 12.94% |
| Lynx1 Capital Management LP | 1,484,693 | $13,318,000 | 12.36% |
| Omega Fund Management, LLC | 2,029,580 | $18,205,000 | 3.73% |
| TCG Crossover Management, LLC | 1,034,222 | $9,277,000 | 3.72% |
| Frazier Life Sciences Management, L.P. | 4,185,757 | $37,546,000 | 3.20% |
| Paradigm Biocapital Advisors LP | 336,229 | $3,016,000 | 0.80% |
| Orbimed Advisors | 4,081,592 | $36,612,000 | 0.59% |
| BVF INC/IL | 1,589,495 | $14,258,000 | 0.57% |
| Kingsbury Capital Investment Advisors LLC | 29,153 | $262,000 | 0.29% |
| Avidity Partners Management LP | 1,207,000 | $10,827,000 | 0.22% |